Actualités et Activités de Oculis
Dirigeants
Voir l'organigramme avec ses 16 principaux dirigeants
Biographies les plus recherchées chez Oculis
- Riad Sherif, Chief Executive Officer and Director
- Geraldine O'Keeffe, Director
- Anthony Rosenberg, Chairman of the Board
Changements de dirigeants chez Oculis
- Daniel Char, a rejoint l'entreprise comme Chief Legal Officer (publié le 2 octobre 2024).
- Sharon Klier, a rejoint l'entreprise comme Chief Development Officer (publié le 18 août 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Oculis.
Pharmacie
Oculis a 1 833 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Eli Lilly (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Imbria Pharmaceuticals vient d'annoncer une levée de fonds de 58 millions de dollars. (publié le 10 avril 2025).
- Clario a acquis NRx Pharmaceuticals (publié le 18 mars 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publié le 12 mars 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Oculis
- Oculis Reports Q3 2023 Financial Results and Provides Company Update | Oculis
- News Releases | Oculis
- Oculis to Present at Upcoming November Investor Conferences | Oculis
- Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema | Oculis
- Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema | Oculis
- Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress | Oculis
- Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase | Oculis
- Oculis to Present at Upcoming September Investor Conferences | Oculis
- Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update | Oculis
- OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery | Oculis
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Oculis
- Oculis sur Wikipédia, Google News & Yahoo Finance en 1-click
- Oculis sur LinkedIn, Twitter & YouTube en 1-click
